MedTrace Logo

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

NCT04606446 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2026-04-16

No results posted yet for this study

Summary

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents

Conditions

Interventions

DRUG

PF-07248144

KAT6 Inhibitor

DRUG

Fulvestrant

Endocrine Therapy

DRUG

Letrozole

Endocrine Therapy

DRUG

Palbociclib

CDK4/6 Inhibitor

DRUG

PF-07220060

CDK4 inhibitor

DRUG

PF-07850327, ARV-471, vepdegestrant

PROTAC (PROteolysis Targeting Chimera) ER degrader

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-16
Primary Completion
2029-07-13
Completion
2029-08-10
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China
  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04606446 on ClinicalTrials.gov